Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.
Identifieur interne : 000C95 ( Main/Corpus ); précédent : 000C94; suivant : 000C96Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.
Auteurs : Allan Giri ; Ankita Das ; Ajoy K. Sarkar ; Ashok K. GiriSource :
- Genes and environment : the official journal of the Japanese Environmental Mutagen Society [ 1880-7046 ] ; 2020.
Abstract
Hydroxychloroquine (HCQ) and Chloroquine (CQ) are two anti-malarial drugs that are now being extensively used by front-line healthcare workers and other common people as a prophylactic drug against the Corona Virus Disease - 19 (COVID-19) in India and as well as in many parts of the world. While only a few in vitro studies have pointed to some efficacy of these drugs as a prophylactic against COVID-19, to date, there are no clinical studies that have established any clinical efficacy of these drugs as a prophylactic. These drugs are commonly used for the treatment of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) because of its immunomodulatory effects. Previously, we have evaluated the genetic toxicology of different drugs and chemicals including antimalarial drug CQ both in vitro and in vivo. Thus, we recognize the need to critically review the mutagenic, genotoxic, and immunomodulatory effects of these drugs, to find out whether it is safe to use as a prophylactic drug against COVID-19. Existing literature suggests that CQ can induce mutagenic and genotoxic effects in multiple test systems and both the drugs have immunomodulatory effects. There was no data available to evaluate the mutagenicity and genotoxicity for HCQ. However, during metabolism about 60% of both the drugs remain unchanged and about 40% of the drugs are metabolized into two metabolites, desethylchloroquine and bisdesethylchloroquine by the action of the cytochrome P450 (CYP) enzymes in the liver. Both HCQ and CQ are immunomodulatory drugs and have the potential to suppress normal immune system activation. In this review, we have elucidated the mechanism of immunomodulation by both HCQ and CQ and highlighted the mutagenic and genotoxic effects from the available literature. This article is written with the sole objective that the reader will be able to recognize the adverse effects of these drugs when consumed by healthy individuals as a prophylactic. Current literature indicates that healthy individuals should refrain from the use of these drugs until further investigation.
DOI: 10.1186/s41021-020-00164-0
PubMed: 32884603
PubMed Central: PMC7462746
Links to Exploration step
pubmed:32884603Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.</title>
<author><name sortKey="Giri, Allan" sort="Giri, Allan" uniqKey="Giri A" first="Allan" last="Giri">Allan Giri</name>
<affiliation><nlm:affiliation>Department of Biomedical Science, Kansas City University of Medicine and Biosciences, Kansas City, MO 64106 USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Das, Ankita" sort="Das, Ankita" uniqKey="Das A" first="Ankita" last="Das">Ankita Das</name>
<affiliation><nlm:affiliation>Department of Environmental Sciences, University of Calcutta, Kolkata, 700019 India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarkar, Ajoy K" sort="Sarkar, Ajoy K" uniqKey="Sarkar A" first="Ajoy K" last="Sarkar">Ajoy K. Sarkar</name>
<affiliation><nlm:affiliation>Intensive Care Unit, Peerless Hospital, B.K. Roy Research Centre, Kolkata, 700094 India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Giri, Ashok K" sort="Giri, Ashok K" uniqKey="Giri A" first="Ashok K" last="Giri">Ashok K. Giri</name>
<affiliation><nlm:affiliation>Molecular Genetics Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032 India.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32884603</idno>
<idno type="pmid">32884603</idno>
<idno type="doi">10.1186/s41021-020-00164-0</idno>
<idno type="pmc">PMC7462746</idno>
<idno type="wicri:Area/Main/Corpus">000C95</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C95</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.</title>
<author><name sortKey="Giri, Allan" sort="Giri, Allan" uniqKey="Giri A" first="Allan" last="Giri">Allan Giri</name>
<affiliation><nlm:affiliation>Department of Biomedical Science, Kansas City University of Medicine and Biosciences, Kansas City, MO 64106 USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Das, Ankita" sort="Das, Ankita" uniqKey="Das A" first="Ankita" last="Das">Ankita Das</name>
<affiliation><nlm:affiliation>Department of Environmental Sciences, University of Calcutta, Kolkata, 700019 India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarkar, Ajoy K" sort="Sarkar, Ajoy K" uniqKey="Sarkar A" first="Ajoy K" last="Sarkar">Ajoy K. Sarkar</name>
<affiliation><nlm:affiliation>Intensive Care Unit, Peerless Hospital, B.K. Roy Research Centre, Kolkata, 700094 India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Giri, Ashok K" sort="Giri, Ashok K" uniqKey="Giri A" first="Ashok K" last="Giri">Ashok K. Giri</name>
<affiliation><nlm:affiliation>Molecular Genetics Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032 India.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Genes and environment : the official journal of the Japanese Environmental Mutagen Society</title>
<idno type="ISSN">1880-7046</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hydroxychloroquine (HCQ) and Chloroquine (CQ) are two anti-malarial drugs that are now being extensively used by front-line healthcare workers and other common people as a prophylactic drug against the Corona Virus Disease - 19 (COVID-19) in India and as well as in many parts of the world. While only a few in vitro studies have pointed to some efficacy of these drugs as a prophylactic against COVID-19, to date, there are no clinical studies that have established any clinical efficacy of these drugs as a prophylactic. These drugs are commonly used for the treatment of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) because of its immunomodulatory effects. Previously, we have evaluated the genetic toxicology of different drugs and chemicals including antimalarial drug CQ both in vitro and in vivo. Thus, we recognize the need to critically review the mutagenic, genotoxic, and immunomodulatory effects of these drugs, to find out whether it is safe to use as a prophylactic drug against COVID-19. Existing literature suggests that CQ can induce mutagenic and genotoxic effects in multiple test systems and both the drugs have immunomodulatory effects. There was no data available to evaluate the mutagenicity and genotoxicity for HCQ. However, during metabolism about 60% of both the drugs remain unchanged and about 40% of the drugs are metabolized into two metabolites, desethylchloroquine and bisdesethylchloroquine by the action of the cytochrome P450 (CYP) enzymes in the liver. Both HCQ and CQ are immunomodulatory drugs and have the potential to suppress normal immune system activation. In this review, we have elucidated the mechanism of immunomodulation by both HCQ and CQ and highlighted the mutagenic and genotoxic effects from the available literature. This article is written with the sole objective that the reader will be able to recognize the adverse effects of these drugs when consumed by healthy individuals as a prophylactic. Current literature indicates that healthy individuals should refrain from the use of these drugs until further investigation.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32884603</PMID>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1880-7046</ISSN>
<JournalIssue CitedMedium="Print"><Volume>42</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Genes and environment : the official journal of the Japanese Environmental Mutagen Society</Title>
<ISOAbbreviation>Genes Environ</ISOAbbreviation>
</Journal>
<ArticleTitle>Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>25</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s41021-020-00164-0</ELocationID>
<Abstract><AbstractText>Hydroxychloroquine (HCQ) and Chloroquine (CQ) are two anti-malarial drugs that are now being extensively used by front-line healthcare workers and other common people as a prophylactic drug against the Corona Virus Disease - 19 (COVID-19) in India and as well as in many parts of the world. While only a few in vitro studies have pointed to some efficacy of these drugs as a prophylactic against COVID-19, to date, there are no clinical studies that have established any clinical efficacy of these drugs as a prophylactic. These drugs are commonly used for the treatment of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) because of its immunomodulatory effects. Previously, we have evaluated the genetic toxicology of different drugs and chemicals including antimalarial drug CQ both in vitro and in vivo. Thus, we recognize the need to critically review the mutagenic, genotoxic, and immunomodulatory effects of these drugs, to find out whether it is safe to use as a prophylactic drug against COVID-19. Existing literature suggests that CQ can induce mutagenic and genotoxic effects in multiple test systems and both the drugs have immunomodulatory effects. There was no data available to evaluate the mutagenicity and genotoxicity for HCQ. However, during metabolism about 60% of both the drugs remain unchanged and about 40% of the drugs are metabolized into two metabolites, desethylchloroquine and bisdesethylchloroquine by the action of the cytochrome P450 (CYP) enzymes in the liver. Both HCQ and CQ are immunomodulatory drugs and have the potential to suppress normal immune system activation. In this review, we have elucidated the mechanism of immunomodulation by both HCQ and CQ and highlighted the mutagenic and genotoxic effects from the available literature. This article is written with the sole objective that the reader will be able to recognize the adverse effects of these drugs when consumed by healthy individuals as a prophylactic. Current literature indicates that healthy individuals should refrain from the use of these drugs until further investigation.</AbstractText>
<CopyrightInformation>© The Author(s) 2020.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giri</LastName>
<ForeName>Allan</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical Science, Kansas City University of Medicine and Biosciences, Kansas City, MO 64106 USA.</Affiliation>
<Identifier Source="GRID">grid.258405.e</Identifier>
<Identifier Source="ISNI">0000 0004 0539 5056</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Das</LastName>
<ForeName>Ankita</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Environmental Sciences, University of Calcutta, Kolkata, 700019 India.</Affiliation>
<Identifier Source="GRID">grid.59056.3f</Identifier>
<Identifier Source="ISNI">0000 0001 0664 9773</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sarkar</LastName>
<ForeName>Ajoy K</ForeName>
<Initials>AK</Initials>
<AffiliationInfo><Affiliation>Intensive Care Unit, Peerless Hospital, B.K. Roy Research Centre, Kolkata, 700094 India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Giri</LastName>
<ForeName>Ashok K</ForeName>
<Initials>AK</Initials>
<Identifier Source="ORCID">0000-0002-2646-4087</Identifier>
<AffiliationInfo><Affiliation>Molecular Genetics Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032 India.</Affiliation>
<Identifier Source="GRID">grid.417635.2</Identifier>
<Identifier Source="ISNI">0000 0001 2216 5074</Identifier>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Genes Environ</MedlineTA>
<NlmUniqueID>101285347</NlmUniqueID>
<ISSNLinking>1880-7046</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Chloroquine</Keyword>
<Keyword MajorTopicYN="N">Genotoxicity</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">Immunomodulation, prophylactic use</Keyword>
<Keyword MajorTopicYN="N">Mutagenicity</Keyword>
</KeywordList>
<CoiStatement>Competing interestsThe authors declares that he have no competing interests.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>07</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32884603</ArticleId>
<ArticleId IdType="doi">10.1186/s41021-020-00164-0</ArticleId>
<ArticleId IdType="pii">164</ArticleId>
<ArticleId IdType="pmc">PMC7462746</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Mutat Res. 1996 Aug;370(1):1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8830801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Postgrad Med J. 1978 Feb;54(628):108-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">273209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2018 Oct;195:1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29981383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Environ Mol Mutagen. 2008 Jul;49(6):488-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18618582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Environ Health Perspect. 2005 May;113(5):517-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15866756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2006 Jun;45(6):703-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16418198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Egypt Soc Parasitol. 2005 Apr;35(1):19-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15880991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nutr Cancer. 1992;18(2):191-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1437656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1986 Oct;175(2):51-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3531844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2005 Dec 5;202(11):1575-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16330816</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1965 Jul;240:3123-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14342342</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neuroimmune Pharmacol. 2020 Jun;15(2):174-180</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32415419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 1970 Dec 14;54(2):247-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5500444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 1973 Nov;32(6):547-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4760478</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2008 Dec 4;456(7222):658-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18820679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Sep 25;12(9):e0184922</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28945807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2015 Dec;96(12):3484-3492</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26459826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):11-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6408923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>An Acad Bras Cienc. 2015 Aug;87(2 Suppl):1487-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26312430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):82-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8278823</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1984 Nov-Dec;138(2-3):133-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6440012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Biol Toxicol. 2006 May;22(3):159-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16532284</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2000 Jun 1;95(11):3460-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10828029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Apr 15;186(8):4794-804</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21398612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Free Radic Biol Med. 1997;22(1-2):321-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8958157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J Acute Cardiovasc Care. 2013 Mar;2(1):77-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24062937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1979 Sep;68(1):41-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">386109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1987 Dec;192(4):233-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2446128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2017 May;76(5):891-897</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27903507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brain Tumor Pathol. 2001;18(2):83-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11908878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacogenomics. 2016 Nov;17(17):1903-1911</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27767381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Genet. 2019 Nov;20(11):657-674</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31358977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutagenesis. 1998 Nov;13(6):619-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9862194</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Soc Exp Biol Med. 1970 Mar;133(3):999-1001</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4907938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2007 Feb;131(2):588-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17296665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 2002 Jun 19;503(1-2):21-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12052500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 2005 Feb;25(3):1025-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15657430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1974 Dec;25(3):391-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4373651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1993 Mar;296(3):199-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7680103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1983 Apr;117(1-2):79-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6339911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 23;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32706953</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1980 Apr;74(2):95-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6990235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2011 Jan 20;469(7330):323-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21248839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 1993 Feb;2 Suppl 1:S13-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8485565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Biol Toxicol. 1986 Sep;2(3):379-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3267457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1985 Dec;158(3):177-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3935920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Toxicol Environ Health B Crit Rev. 2009;12(5-6):334-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20183526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 16;382(16):1564-1567</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32182409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheumatol. 2016 Jan;68(1):184-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26316040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2015 May 1;194(9):4089-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25821216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2013 May;131(5):1443-6.e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23541328</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):19-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6603165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Res Ther. 2012 Jun 27;14(3):R155</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22734582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2018 May 17;10(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Res Ther. 2017 Aug 9;19(1):183</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28793932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 2007 Jan-Feb;635(1):17-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17157055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1989 Mar;222(3):161-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2646533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutagenesis. 2012 Jul;27(4):387-413</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22228823</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biull Eksp Biol Med. 1976 Jul;82(7):879-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1085185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Environ Mol Mutagen. 2001;38(1):69-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11473390</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutagenesis. 1990 May;5(3):267-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2200947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mutat Res. 1980 Jul;78(3):253-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7432360</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Toxicol Environ Health B Crit Rev. 2020 May 18;23(4):177-181</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32281481</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32884603 |texte= Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32884603" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |